Jpmorgan Chase & CO Phathom Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 134,357 shares of PHAT stock, worth $2.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134,357

Previous 138,452 2.96%

Holding current value

$2.54 Million

Previous $1.47 Million 5.92%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$8.97 - $12.05 $36,732 - $49,344	-4,095 Reduced 2.96%	134,357 $1.38 Million
Q1 2024 May 10, 2024	SELL	$6.21 - $11.05 $47,102 - $83,814	-7,585 Reduced 5.19%	138,452 $1.47 Million
Q4 2023 Feb 12, 2024	BUY	$6.99 - $10.71 $8,954 - $13,719	1,281 Added 0.88%	146,037 $1.33 Million
Q3 2023 Nov 14, 2023	BUY	$10.26 - $15.7 $110,397 - $168,932	10,760 Added 8.03%	144,756 $1.5 Million
Q2 2023 Aug 11, 2023	BUY	$7.28 - $14.32 $2,977 - $5,856	409 Added 0.31%	133,996 $1.92 Million
Q1 2023 May 18, 2023	BUY	$6.19 - $12.36 $116,328 - $232,281	18,793 Added 16.37%	133,587 $953,000
Q1 2023 May 11, 2023	SELL	$6.19 - $12.36 $88,857 - $177,427	-14,355 Reduced 11.12%	114,794 $819,000
Q4 2022 Feb 13, 2023	SELL	$9.18 - $11.53 $387,588 - $486,808	-42,221 Reduced 24.64%	129,149 $1.45 Million
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $3,766 - $7,060	583 Added 0.34%	171,370 $1.9 Million
Q2 2022 Aug 11, 2022	SELL	$6.2 - $15.5 $29,605 - $74,012	-4,775 Reduced 2.72%	170,787 $1.44 Million
Q1 2022 May 11, 2022	BUY	$11.55 - $20.06 $34,661 - $60,200	3,001 Added 1.74%	175,562 $2.39 Million
Q4 2021 Feb 10, 2022	BUY	$17.83 - $33.15 $63,706 - $118,444	3,573 Added 2.11%	172,561 $3.39 Million
Q3 2021 Nov 12, 2021	BUY	$30.69 - $36.83 $5.19 Million - $6.22 Million	168,988 New	168,988 $5.43 Million

Others Institutions Holding PHAT

# of Institutions

125

Shares Held

59M

Call Options Held

467K

Put Options Held

34.9K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $742M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Phathom Pharmaceuticals, Inc. Transaction History